CHAMPIONS BIOTECHNOLOGY, INC. Form 8-K November 04, 2010

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 2, 2010

#### CHAMPIONS BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other Jurisdiction of Incorporation) **0-17263** (Commission File Number)

**52-1401755** (IRS Employer Identification No.)

# Science and Technology Park at Johns Hopkins855 N. Wolfe Street, Suite 619, Baltimore, MD(Address of Principal Executive Offices)(Zip Code)

Registrant s telephone number, including area code: (410) 369-0365

#### Inapplicable

(Former name or former address if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### INFORMATION TO BE INCLUDED IN THE REPORT

### Item 8.01. Other Events.

Reference is made to the press release issued by the Registrant on November 2, 2010, the text of which is attached hereto as Exhibit 99.1.

#### Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

The following exhibits are filed herewith:

Exhibit No.

99.1 Press Release dated November 2, 2010

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

## CHAMPIONS BIOTECHNOLOGY, INC.

(Registrant)

Date: November 4, 2010

By: <u>/s/ Mark Schonau</u> Mark Schonau Chief Financial Officer

2